Rep. Laura Friedman discloses trade(s) in HOLX, CVR
Laura Friedman (CA30) disclosed 1 transaction, traded Apr 8: 0 purchases and 1 sale.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| Apr 8 | HOLX | to be paid in 2026-27. Hologic, Inc. | Sell (partial) | $1,001 - $15,000 | Self |
ORIGINAL FILING ↗ALL FILINGS BY LAURA FRIEDMAN →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. representative has filed financial disclosures showing transactions in two publicly traded companies: Hologic, a medical device and diagnostics firm, and CVR Energy, a refining and midstream energy company. Congressional stock trading disclosures are part of the public record under the STOCK Act and related transparency rules, allowing tracking of lawmakers' personal investment activity. Such disclosures can signal confidence or hedging in specific sectors and are monitored by market participants and governance observers for potential conflicts of interest or sector positioning.
Sources (1)
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Hon. Laura FriedmanSep 28, 2026View the original filing at the House Clerk ↗
How This Could Play Out
First assessed Sep 28
Resolved
LIKELYThis outcome—routine disclosure filing processed and archived without controversy—would have no discernible market impact, as such filings are procedurally normal and do not signal new information about the underlying companies or legislative intent.
Status quo
LIKELYIf the disclosure remains a standard administrative record with no follow-up scrutiny or media amplification, HOLX and CVR would trade on their own fundamentals and sector dynamics rather than any signal from a single legislator's portfolio rebalancing.
Worsens
UNLIKELYShould the timing or pattern of these trades trigger ethics investigations or media narratives about insider trading or conflicts of interest, such scrutiny could create reputational pressure on the companies involved and potentially invite broader Congressional trading reform discussions that affect investor sentiment in healthcare and energy sectors.
SPONSORED
More on Congressional Stock Trading
- Rep. James A. Himes files a Periodic Transaction ReportOct 20
- Rep. Jonathan Jackson discloses trade(s) in DDOG, EL, GH, TYG, VSATOct 19
- Rep. Michael Rulli discloses trade(s) in GOOG, WSBCOct 19
- Attorneys for Ilhan Omar seek return of items taken during home searchOct 17
- Rep. Laurel Lee discloses trade(s) in BAC, NOKBFOct 16
- Rep. Scott H. Peters files a Periodic Transaction ReportOct 15
Get the market digest by email
One email each morning: yesterday's key story and what it means for markets. Free.